AzTrials
AzTrials

Multiple MyelomaPhase 3NCT06152575

MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)

A Phase 3 study testing Elranatamab, Elotuzumab and Pomalidomide in people with Multiple Myeloma, run by Pfizer at 270 sites in 27 countries.

Recruiting

Looking for participants now. Contact the study team or a site below to ask about taking part.

Sites and contacts
Official record
Search all trials

Trial summary

The purpose of this study is to learn about the study medicine called elranatamab.This study aims to compare elranatamab to other medicines for the treatment of MM (a type of cancer). This study is seeking participants who: Are 18 years of age or older and have MM. Have received treatments before for MM. Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Multiple Myeloma
What is being tested?
Elranatamab, Elotuzumab and Pomalidomide
Could I receive a placebo?
No, everyone receives an active treatment
How many people
492 participants
Where
270 sitesin 27 countries
Study dates
8 Feb 2024to 30 Dec 2027
Phase
Phase 3
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Prior diagnosis of multiple myeloma as defined by International Myeloma Working Group (IMWG) criteria and previously received 1 to 4 prior lines of therapy including prior anti-cluster of differentiation 38 (CD38) antibody and prior lenalidomide.
  • Documented evidence of progressive disease or failure to achieve a response to last line of therapy per IMWG criteria.
  • Measurable disease defined as at least 1 of the following: (a) Serum M-protein ≥0.5 g/dL; (b) Urinary M-protein excretion ≥200 mg/24 hours; (c) Serum involved immunoglobulin FLC ≥10 mg/dL AND abnormal serum immunoglobulin kappa to lambda FLC ratio (<0.26 or >1.65).
  • Have clinical laboratory values within the specified range.
  • ECOG (Eastern Cooperative Oncology Group) performance status ≤2.
  • Not pregnant or breastfeeding and willing to use contraception.

Who cannot join

  • Smoldering multiple myeloma.
  • Plasma cell leukemia.
  • Amyloidosis.
  • Polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy and skin abnormalities (POEMS) syndrome.
  • Known central nervous system (CNS) involvement or clinical signs of myelomatous meningeal involvement.
  • Stem cell transplant within 12 weeks prior to enrolment, or active graft versus host disease.
Show all 12Show fewer
  • Any active, uncontrolled bacterial, fungal, or viral infection.
  • Any other active malignancy within 3 years prior to enrolment (exceptions include, adequately treated basal cell or squamous cell skin cancer, carcinoma in situ)
  • Previous treatment with a B cell maturation antigen (BCMA)-directed therapy or CD3-redirecting therapy.
  • Unable to receive investigator's choice therapy.
  • Live attenuated vaccine within 4 weeks of the first dose of study intervention.
  • Administration with an investigational product (e.g. drug or vaccine) within 30 days preceding the first dose of study intervention used in this study.

Trial locations and contacts

270 sites in 27 countries. Contact the study team or a site near you to ask about taking part.

Pfizer CT.gov Call Center contact

1-800-718-1021

ClinicalTrials.gov_Inquiries@pfizer.com

270 sites in 27 countries

United States100 sites, 93 recruiting

  • American Oncology Partners, P.A. Dba MidAmerica Cancer Care

    Belton, Missouri, 64012

    Recruiting

  • Beverly Hills Cancer Center

    Beverly Hills, California, 90211

    Recruiting

  • Beth Israel Deaconess Medical Center

    Boston, Massachusetts, 02215

    Recruiting

  • BIDMC Research Pharmacy

    Boston, Massachusetts, 02215

    Recruiting

  • Endeavor Health - Swedish Hospital

    Chicago, Illinois, 60625

    Recruiting

  • Oncology Hematology Care Clinical Trials, LLC

    Cincinnati, Ohio, 45211

    Recruiting

  • TriHealth Cancer Institute-Good Samaritan Hospital

    Cincinnati, Ohio, 45220

    Recruiting

  • Oncology Hematology Care Clinical Trials, LLC

    Cincinnati, Ohio, 45236

    Recruiting

  • The Jewish Hospital

    Cincinnati, Ohio, 45236

    Recruiting

  • Oncology Hematology Care Clinical Trials, LLC

    Cincinnati, Ohio, 45242

    Recruiting

  • TriHealth Cancer Institute- Thomas Comprehensive Care Center

    Cincinnati, Ohio, 45242

    Recruiting

  • Oncology Hematology Care Clinical Trials, LLC

    Cincinnati, Ohio, 45245

    Recruiting

  • Cleveland Clinic

    Cleveland, Ohio, 44195

    Recruiting

  • Clovis Community Medical Center

    Clovis, California, 93611

    Recruiting

  • Community Cancer Institute

    Clovis, California, 93611

    Recruiting

  • Sylvester Comprehensive Cancer Center - The Lennar Foundation Medical Center

    Coral Gables, Florida, 33146

    Recruiting

  • Baylor University Medical Center, Investigational Drug Services, Department of Pharmacy

    Dallas, Texas, 75246

    Recruiting

  • Baylor University Medical Center

    Dallas, Texas, 75246

    Recruiting

  • University of Miami Hospital and Clinics - Deerfield Beach

    Deerfield Beach, Florida, 33442

    Recruiting

  • Sylvester Comprehensive Cancer Center- Doral

    Doral, Florida, 33166

    Recruiting

  • Clinical Research Advisors (Encino Satellite Location)

    Encino, California, 91316

    Recruiting

  • Endeavor Health - Evanston Hospital

    Evanston, Illinois, 60201

    Recruiting

  • Sanford Fargo Medical Center

    Fargo, North Dakota, 58102

    Recruiting

  • UCHealth Poudre Valley Hospital

    Fort Collins, Colorado, 80524

    Recruiting

  • UCHealth Harmony

    Fort Collins, Colorado, 80528

    Recruiting

  • University of California San Francisco

    Fresno, California, 93701

    Recruiting

  • Community Regional Medical Center

    Fresno, California, 93721

    Recruiting

  • Endeavor Health - Glenbrook Hospital Ambulatory Care Center

    Glenview, Illinois, 60026

    Recruiting

  • Western Regional Medical Center, Inc. dba. City of Hope Phoenix

    Goodyear, Arizona, 85338

    Active, not recruiting

  • UCHealth Greeley Hospital

    Greeley, Colorado, 80634

    Recruiting

  • St Francis Cancer Center

    Greenville, South Carolina, 29607

    Active, not recruiting

  • WMCHealth Advanced Physician Services

    Hawthorne, New York, 10532

    Active, not recruiting

  • Endeavor Health - Highland Park Hospital Health Center 1

    Highland Park, Illinois, 60035

    Recruiting

  • Sylvester Comprehensive Cancer Center - Hollywood

    Hollywood, Florida, 33021

    Recruiting

  • Houston Methodist Cancer Center Infusion

    Houston, Texas, 77030

    Recruiting

  • Houston Methodist Hospital - Department of Pharmacy

    Houston, Texas, 77030

    Recruiting

  • Houston Methodist Hospital Cancer Center

    Houston, Texas, 77030

    Recruiting

  • Houston Methodist Clear Lake Hospital (St. John)

    Houston, Texas, 77058

    Recruiting

  • Houston Methodist Willowbrook Hospital

    Houston, Texas, 77070

    Recruiting

  • Houston Methodist West Hospital

    Houston, Texas, 77094

    Recruiting

  • MIVA Medical

    Independence, Missouri, 64057

    Recruiting

  • Community Health Network, Inc.

    Indianapolis, Indiana, 46227

    Recruiting

  • Community Health Network, Inc.

    Indianapolis, Indiana, 46250

    Recruiting

  • Community Health Network, Inc.

    Indianapolis, Indiana, 46256

    Recruiting

  • Hoag Health Center Irvine

    Irvine, California, 92618

    Active, not recruiting

  • Hoag Hospital Irvine

    Irvine, California, 92618

    Active, not recruiting

  • American Oncology Partners, P.A. Dba MidAmerica Cancer Care

    Kansas City, Kansas, 66112

    Recruiting

  • Kansas City VA Medical Center

    Kansas City, Missouri, 64128

    Recruiting

  • American Oncology Partners, P.A. Dba MidAmerica Cancer Care

    Kansas City, Missouri, 64132

    Recruiting

  • Northwell Health/ RJ Zuckerberg Cancer Center

    Lake Success, New York, 11042

    Recruiting

  • Ascentist Doctors' Hospital

    Leawood, Kansas, 66211

    Recruiting

  • Bryan Medical Center

    Lincoln, Nebraska, 68506

    Recruiting

  • NHO Revive Research Institute, LLC

    Lincoln, Nebraska, 68506

    Recruiting

  • UCHealth Longs Peak Hospital

    Longmont, Colorado, 80504

    Recruiting

  • UCHealth Longs Peak Medical Center

    Longmont, Colorado, 80504

    Recruiting

  • Clinical Research Advisors (Korea Town Satellite Location)

    Los Angeles, California, 90020

    Recruiting

  • Clinical Research Advisors (West Hollywood Satellite Location)

    Los Angeles, California, 90048

    Recruiting

  • Valkyrie Clinical Trials

    Los Angeles, California, 90067

    Recruiting

  • UCHealth - Medical Center of the Rockies

    Loveland, Colorado, 80538

    Recruiting

  • Joe Arrington Cancer Research and Treatment Center

    Lubbock, Texas, 79410

    Recruiting

  • University of Wisconsin Carbone Cancer Center - Eastpark Medical Center

    Madison, Wisconsin, 53718

    Recruiting

  • University of Wisconsin Carbone Cancer Center-University Hospital

    Madison, Wisconsin, 53792

    Recruiting

  • North Shore University Hospital

    Manhasset, New York, 11030

    Recruiting

  • American Oncology Partners, P.A. Dba MidAmerica Cancer Care

    Merriam, Kansas, 66204

    Recruiting

  • Sylvester Comprehensive Cancer Center

    Miami, Florida, 33136

    Recruiting

  • University of Miami Hospital and Clinics - Griffin Cancer Research Building

    Miami, Florida, 33136

    Recruiting

  • University of Miami Hospital and Clinics

    Miami, Florida, 33136

    Recruiting

  • Baptist Hospital of Miami

    Miami, Florida, 33176

    Recruiting

  • Miami Cancer Institute at Baptist Health, Inc.

    Miami, Florida, 33176

    Recruiting

  • Sylvester Comprehensive Cancer Center- Kendall

    Miami, Florida, 33176

    Recruiting

  • Infirmary Cancer Care

    Mobile, Alabama, 36607

    Recruiting

  • WVU Cancer Institute

    Morgantown, West Virginia, 26506

    Recruiting

  • Atlantic Health System Morristown Medical Center

    Morristown, New Jersey, 07960

    Recruiting

  • Ascension St. Thomas Hospital

    Nashville, Tennessee, 37203

    Recruiting

  • Tennessee Oncology, PLLC - Investigational Drug Services

    Nashville, Tennessee, 37203

    Recruiting

  • Tennessee Oncology, PLLC - Nashville Elliston Place Plaza Center for Blood Cancers

    Nashville, Tennessee, 37203

    Recruiting

  • Tennessee Oncology, PLLC - Nashville Elliston Place Plaza DDU

    Nashville, Tennessee, 37203

    Recruiting

  • Tennessee Oncology, PLLC - Nashville Elliston Place Plaza Medical Oncology & Hematology

    Nashville, Tennessee, 37203

    Recruiting

  • Long Island Jewish Medical Center

    New Hyde Park, New York, 11040

    Recruiting

  • Hoag Memorial Hospital Presbyterian

    Newport Beach, California, 92663

    Active, not recruiting

  • Mission Community Hospital (Satellite Site)

    Panorama City, California, 91402

    Recruiting

  • AHN West Penn Hospital

    Pittsburgh, Pennsylvania, 15224

    Recruiting

  • BRCR Global

    Plantation, Florida, 33322

    Recruiting

  • BRCR Medical Center Inc

    Plantation, Florida, 33322

    Recruiting

  • Brcr Medical Center, Inc.

    Plantation, Florida, 33322

    Recruiting

  • HCA Florida Westside Hospital

    Plantation, Florida, 33324

    Recruiting

  • Rodhe Island Hospital

    Providence, Rhode Island, 02903

    Recruiting

  • The Miriam Hospital

    Providence, Rhode Island, 02906

    Recruiting

  • University of California Davis (UC Davis) Comprehensive Cancer Center

    Sacramento, California, 95817

    Recruiting

  • University of California

    Sacramento, California, 95817

    Recruiting

  • Simmons Cancer Institute at SIU

    Springfield, Illinois, 62702

    Recruiting

  • Springfield Clinic Main Campus

    Springfield, Illinois, 62703

    Recruiting

  • HSHS St. John's Hospital

    Springfield, Illinois, 62769

    Recruiting

  • Springfield Memorial Hospital

    Springfield, Illinois, 62781

    Recruiting

  • Houston Methodist Sugar Land Hospital

    Sugar Land, Texas, 77479

    Recruiting

  • BRCR Medical Center Inc.

    Tamarac, Florida, 33321

    Recruiting

  • Baylor Scott & White Medical Center - Temple

    Temple, Texas, 76508

    Recruiting

  • Houston Methodist The Woodlands Hospital

    The Woodlands, Texas, 77385

    Recruiting

  • Westchester Medical Center

    Valhalla, New York, 10595

    Active, not recruiting

  • Midwestern Regional Medical Center, Inc. dba City of Hope Chicago

    Zion, Illinois, 60099

    Recruiting

Other trials in United States

Brazil19 sites, 19 recruiting

  • Hospital Amaral Carvalho

    Jaú, São Paulo, 17210-080

    Recruiting

  • Instituto Oncomed de Educação e Pesquisa

    Niterói, Rio de Janeiro, 24220-070

    Recruiting

  • Oncomed Clínica Oncológica

    Niterói, Rio de Janeiro, 24220-300

    Recruiting

  • Hospital Moinhos de Vento

    Porto Alegre, Rio Grande do Sul, 90035-001

    Recruiting

  • Centro Gaucho Integrado De Oncologia, Hematologia, Ensino E Pesquisa

    Porto Alegre, Rio Grande do Sul, 90110-270

    Recruiting

  • Centro de Pesquisa Clínica - Área Administrativa

    Porto Alegre, Rio Grande do Sul, 90850-170

    Recruiting

  • Hospital Mae de Deus

    Porto Alegre, Rio Grande do Sul, 90880-480

    Recruiting

  • Hospital das Clínicas da Faculdade de Medicina de Ribeirão Preto da Universidade de São Paulo (USP)

    Ribeirão Preto, São Paulo, 14051-140

    Recruiting

  • Instituto de Educação, Pesquisa e Gestão em Saúde

    Rio de Janeiro, 20775-001

    Recruiting

  • Americas Centro de Oncologia Integrado

    Rio de Janeiro, 22775001

    Recruiting

  • Instituto de Educação, Pesquisa e Gestão em Saúde

    Rio de Janeiro, 22793-080

    Recruiting

  • Instituto D'Or de Pesquisa e Ensino (IDOR) - Filial Salvador

    Salvador, Estado de Bahia, 41253-190

    Recruiting

  • Instituto D'Or de Pesquisa e Ensino (IDOR)

    São Paulo, São Paulo, 04543-000

    Recruiting

  • ESHO Empresa de Serviços Hospitalares S.A/ Hospital Samaritano de Higienópolis

    São Paulo, 01232-010

    Recruiting

  • Instituto D'Or de Pesquisa e Ensino (IDOR)

    São Paulo, 01401-002

    Recruiting

  • HU UNIFESP / SPDM - Hospital São Paulo

    São Paulo, 04024-002

    Recruiting

  • Universidade Federal de Sao Paulo

    São Paulo, 04024-002

    Recruiting

  • Clínica Médica São Germano S/S Ltda

    São Paulo, 04537-080

    Recruiting

  • Clínica Médica São Germano LTDA

    SP, São Paulo, 04537-080

    Recruiting

Other trials in Brazil

United Kingdom18 sites, 18 recruiting

  • Betsi Cadwaladr University Health Board

    Bangor, Gwynedd, LL57 2PW

    Recruiting

  • Queen Elizabeth Hospital Birmingham

    Birmingham, England, B15 2TH

    Recruiting

  • Glan Clwyd Hospital

    Bodelwyddan, Denbighshire [SIR Ddinbych Gb-ddb], LL18 5UJ

    Recruiting

  • Royal Bournemouth Hospital

    Bournemouth, Dorset, BH7 7DW

    Recruiting

  • Kent and Canterbury Hospital

    Canterbury, CT1 3NG

    Recruiting

  • Eastbourne District General Hospital

    Eastbourne, EAST Sussex, BN21 2UD

    Recruiting

  • Barts Health NHS Trust

    London, Greater London, E1 1BB

    Recruiting

  • St Bartholomew's Hospital

    London, London, CITY of, EC1A 7BE

    Recruiting

  • Guy's & St Thomas' NHS Foundation Trust

    London, London, CITY of, SE1 9RT

    Recruiting

  • King's College Hospital

    London, London, CITY of, SE5 9RL

    Recruiting

  • Royal Marsden Hospital (Sutton)

    London, Sutton, SM2 5PT

    Recruiting

  • Maidstone Hospital

    Maidstone, KENT, ME16 9QQ

    Recruiting

  • Milton Keynes Hospital

    Milton Keynes, Buckinghamshire, MK6 5LD

    Recruiting

  • Churchill Hospital

    Oxford, Oxfordshire, OX3 7LE

    Recruiting

  • Poole Hospital

    Poole, Dorset, BH15 2JB

    Recruiting

  • Royal Stoke University Hospital

    Stoke-on-Trent, Staffordshire, ST4 6QG

    Recruiting

  • New Cross Hospital

    Wolverhampton, WV10 0QP

    Recruiting

  • Worthing Hospital

    Worthing, EAST Sussex, BN11 2DH

    Recruiting

Other trials in United Kingdom

France15 sites, 13 recruiting

  • Centre Hospitalier de la Côte Basque

    Bayonne, 64109

    Recruiting

  • Centre Hospitalier Universitaire de Poitiers

    City/Town/Village, Vienne, 86021

    Recruiting

  • Henri Mondor Hospital

    Créteil, Val-de-marne, 94010

    Recruiting

  • CHD Vendee

    La Roche-sur-Yon, 85925

    Recruiting

  • Centre Hospitalier du Mans

    Le Mans, 72037

    Recruiting

  • Centre Hospitalier Universitaire de Nantes - L' Hopital l'hôtel-Dieu

    Nantes, Pays de la Loire Region, 44000

    Recruiting

  • Hôpital Universitaire Necker Enfants Malades

    Paris, 75015

    Recruiting

  • Hopitaux Universitaires Paris Centre-Hopital Cochin

    Paris, 75679

    Recruiting

  • CHU Bordeaux Haut-Leveque

    Pessac, Aquitaine, 33600

    Recruiting

  • Hôpital NOVO

    Pontoise, Val-d'oise, 95300

    Recruiting

  • Centre Hospitalier de Cornouaille

    Quimper, 29107

    Recruiting

  • Institut Universitaire du Cancer Toulouse - Oncopole - CHU de TOULOUSE

    Toulouse, Haute-garonne, 31100

    Recruiting

  • Centre Hospitalier Régional Universitaire de Tours - Hôpital Bretonneau

    Tours, 37044

    Recruiting

  • Centre Hospitalier Bretagne Atlantique

    Vannes, 56000

    Active, not recruiting

  • Centre Hospitalier Bretagne Atlantique

    Vannes, 56017

    Active, not recruiting

Other trials in France

Japan14 sites, 14 recruiting

  • Nippon Medical School Hospital

    Bunkyo-ku, Tokyo, 113-8603

    Recruiting

  • Kagoshima University Hospital

    Kagoshima, 890-8520

    Recruiting

  • Kobe City Medical Center General Hospital

    Kobe, Hyōgo, 650-0047

    Recruiting

  • Yamanashi Prefectural Central Hospital

    Kofu, Yamanashi, 400-8506

    Recruiting

  • Japanese Foundation for Cancer Research

    Koto, Tokyo, 135-8550

    Recruiting

  • The Cancer Institute Hospital of JFCR

    Koto, Tokyo, 135-8550

    Recruiting

  • University Hospital,Kyoto Prefectural University of Medicine

    Kyoto, 602-8566

    Recruiting

  • Gunma University Hospital

    Maebashi, Gunma, 371-8511

    Recruiting

  • Ehime Prefectural Central Hospital

    Matsuyama, Ehime, 790-0024

    Recruiting

  • National Hospital Organization Okayama Medical Center

    Okayama, 701-1192

    Recruiting

  • National Hospital Organization Shibukawa Medical Center

    Shibukawa, Gunma, 377-0280

    Recruiting

  • Iwate Medical University Hospital

    Shiwa-gun Yahaba-cho, Iwate, 028-3695

    Recruiting

  • Toyohashi Municipal Hospital

    Toyohashi, Aichi-ken, 441-8570

    Recruiting

  • Yamagata University Hospital

    Yamagata, 990-9585

    Recruiting

Other trials in Japan

Italy12 sites, 4 recruiting

  • Azienda Ospedaliero Universitaria delle Marche

    Ancona, The Marches, 60126

    Recruiting

  • IRCCS Azienda Ospedaliero-Universitaria di Bologna, Policlinico di Sant'Orsola

    Bologna, 40138

    Active, not recruiting

  • Azienda Ospedaliera Universitaria Careggi

    Florence, Tuscany, 50134

    Active, not recruiting

  • Azienda Socio Sanitaria Ovest milanese

    Legnano, Milano, 20025

    Active, not recruiting

  • IRCCS - Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori"

    Meldola (FC), 47014

    Active, not recruiting

  • P.O. San Carlo Borromeo- ASST SANTI PAOLO E CARLO

    Milan, Lombardy, 20153

    Recruiting

  • Istituto Europeo di Oncologia IRCCS

    Milan, 20141

    Active, not recruiting

  • ASST Santi Paolo e Carlo Ospedale San Paolo

    Milan, 20142

    Recruiting

  • A.O.U. Policlinico Paolo Giaccone

    Palermo, Sicily, 90127

    Active, not recruiting

  • Ospedale Civile dello Spirito Santo

    Pescara, 65124

    Recruiting

  • Azienda Ospedaliero Universitaria Pisana

    Pisa, Tuscany, 56126

    Active, not recruiting

  • Azienda Ospedaliero-Universitaria Città della Salute e della Scienza di Torino

    Turin, Piedmont, 10126

    Active, not recruiting

Other trials in Italy

Spain12 sites

  • Institut Català d'Oncologia (ICO) - Badalona

    Badalona, Barcelona [barcelona], 08916

    Active, not recruiting

  • OSI Ezkerraldea-Enkarterri-Cruces - Hospital Universitario Cruces

    Barakaldo, Basque Country, 48903

    Active, not recruiting

  • Hospital Clínic de Barcelona

    Barcelona, Catalunya [cataluña], 08036

    Active, not recruiting

  • Institut Català d'Oncologia (ICO) - Girona

    Girona, Girona [gerona], 17007

    Active, not recruiting

  • Hospital General Universitario Gregorio Marañon

    Madrid, 28007

    Active, not recruiting

  • Hospital Universitario HM Sanchinarro

    Madrid, 28050

    Active, not recruiting

  • H.R.U Málaga - Hospital General

    Málaga, 29010

    Active, not recruiting

  • Hospital General Universitario Morales Meseguer

    Murcia, Galicia [galicia], 30008

    Active, not recruiting

  • Hospital Universitario de Salamanca - Complejo Asistencial Universitario de Salamanca

    Salamanca, 37007

    Active, not recruiting

  • Hospital Universitari Mutua Terrassa

    Terrassa, Barcelona [barcelona], 08221

    Active, not recruiting

  • ASCIRES ECG Médica S.L

    Valencia, Valenciana, Comunitat, 46004

    Active, not recruiting

  • Hospital Universitari i Politecnic La Fe

    Valencia, 46026

    Active, not recruiting

Other trials in Spain

Germany9 sites, 9 recruiting

  • Vivantes Klinikum Am Urban

    Berlin, 10249

    Recruiting

  • Vivantes Klinikum Am Urban

    Berlin, 10967

    Recruiting

  • Universitätsklinikum Bonn

    Bonn, North Rhine-Westphalia, 53127

    Recruiting

  • Medizinische Universität Lausitz - Carl Thiem

    Cottbus, 03048

    Recruiting

  • Universitaetsklinikum Freiburg

    Freiburg im Breisgau, Baden-Wurttemberg, 79106

    Recruiting

  • St. Barbara-Klinik Hamm-Heessen

    Hamm, 59073

    Recruiting

  • Klinikum Nürnberg Nord

    Nuremberg, Bavaria, 90419

    Recruiting

  • Robert Bosch Krankenhaus GmbH

    Stuttgart, Baden-Wurttemberg, 70376

    Recruiting

  • Universitaetsklinikum Ulm

    Ulm, Baden-Wurttemberg, 89081

    Recruiting

Other trials in Germany

Australia7 sites, 7 recruiting

  • Sunshine Coast University Hospital

    Birtinya, Queensland, 4575

    Recruiting

  • Blacktown Hospital

    Blacktown, New South Wales, 2148

    Recruiting

  • Royal Brisbane and Women's Hospital

    Brisbane, Queensland, 4029

    Recruiting

  • Concord Repatriation General Hospital

    Concord, New South Wales, 2139

    Recruiting

  • St Vincent's Hospital (Melbourne)

    Fitzroy, Victoria, 3065

    Recruiting

  • Barwon Health

    Geelong, Victoria, 3220

    Recruiting

  • Sir Charles Gairdner Hospital, Haematology Clinical Trials

    Nedlands, Western Australia, 6009

    Recruiting

Other trials in Australia

Croatia7 sites, 7 recruiting

  • Klinicki bolnicki centar Osijek

    Osijek, 31000

    Recruiting

  • Klinicki bolnicki centar Rijeka

    Rijeka, 51000

    Recruiting

  • Klinicki bolnicki centar Split

    Split, 21 000

    Recruiting

  • Sestre milosrdnice University Hospital Center

    Zagreb, 10 000

    Recruiting

  • University Hospital Center Zagreb

    Zagreb, 10 000

    Recruiting

  • Klinicka bolnica Dubrava

    Zagreb, 10000

    Recruiting

  • Klinicka bolnica Merkur

    Zagreb, 10000

    Recruiting

Other trials in Croatia

Chile6 sites, 6 recruiting

  • FALP

    Providencia, Santiago Metropolitan, 7500836

    Recruiting

  • FALP

    Providencia, Santiago Metropolitan, 7500966

    Recruiting

  • FALP

    Santiago, Santiago Metropolitan, 7500921

    Recruiting

  • Clínica Inmunocel

    Santiago, Santiago Metropolitan, 7580206

    Recruiting

  • Clínica Universidad de Los Andes

    Santiago, Santiago Metropolitan, 7620157

    Recruiting

  • Clínica Alemana de Santiago

    Santiago, Santiago Metropolitan, 7650568

    Recruiting

Other trials in Chile

Belgium5 sites, 5 recruiting

  • UZ Brussel

    Brussels, Bruxelles-capitale, Région de, 1090

    Recruiting

  • Grand Hôpital de Charleroi

    Gilly, Hainaut, 6060

    Recruiting

  • Centre Hospitalier Epicura

    Hornu, Hainaut, 7301

    Recruiting

  • CHR Verviers - La Tourelle

    Verviers, Liège, 4800

    Recruiting

  • Université Catholique de Louvain-Namur - Centre Hospitalier Universitaire Dinant-Godinne - Site Godi

    Yvoir, Namur, 5530

    Recruiting

Other trials in Belgium

Greece5 sites

  • University General Hospital of Alexandroupoli

    Alexandroupoli, Anatolikí Makedonía KAI Thráki, 681 00

    Active, not recruiting

  • Alexandra General Hospital of Athens

    Athens, Attikí, 115 28

    Active, not recruiting

  • University Hospital of Ioannina

    Ioannina, Ípeiros, 455 00

    Active, not recruiting

  • "Theagenio" Cancer Hospital of Thessaloniki

    Thessaloniki, Kentrikí Makedonía, 54639

    Active, not recruiting

  • G. Papanikolaou General Hospital

    Thessaloniki, Thessaloníki, 570 10

    Active, not recruiting

Other trials in Greece

Israel5 sites, 5 recruiting

  • Soroka Medical Center

    Beersheba, Southern District, 8410101

    Recruiting

  • Hadassah Medical Center

    Jerusalem, Jerusalem, 9112001

    Recruiting

  • Rabin Medical Center

    Petah Tikva, Central District, 4910021

    Recruiting

  • Sheba Medical Center

    Ramat Gan, Central District, 5265601

    Recruiting

  • Sourasky Medical Center

    Tel Aviv, TELL ABĪB, 6423906

    Recruiting

Other trials in Israel

Argentina4 sites, 4 recruiting

  • Instituto Alexander Fleming

    Ciudad Autónoma de Buenos Aires, Buenos Aires, C1426ANZ

    Recruiting

  • Hospital Italiano de Buenos Aires

    Ciudad de Buenos Aires, Buenos Aires F.D., C1199ABB

    Recruiting

  • Hospital Italiano de La Plata

    La Plata, 1900

    Recruiting

  • Hospital Universitario Austral

    Pilar, Buenos Aires, 1629

    Recruiting

Other trials in Argentina

Norway4 sites, 4 recruiting

  • Akershus Universitetssykehus

    Lørenskog, Akershus, 1478

    Recruiting

  • Oslo Universitetssykehus Ullevål

    Oslo, 0450

    Recruiting

  • Sykehuset i Vestfold

    Tønsberg, Vestfold, 3103

    Recruiting

  • St. Olavs Hospital

    Trondheim, Sør-trøndelag, 7030

    Recruiting

Other trials in Norway

Slovakia4 sites

  • Fakultna nemocnica s poliklinikou F.D.Roosevelta Banska Bystrica

    Banská Bystrica, Banská Bystrica Region, 97517

    Active, not recruiting

  • Narodny onkologicky ustav

    Bratislava, 833 10

    Active, not recruiting

  • Univerzitna nemocnica Bratislava, Nemocnica sv. Cyrila a Metoda

    Bratislava, 851 07

    Active, not recruiting

  • Univerzitna Nemocnica L. Pasteura Kosice

    Košice, Košice Region, 040 11

    Active, not recruiting

Other trials in Slovakia

Canada3 sites, 3 recruiting

  • The Moncton Hospital

    Moncton, New Brunswick, E1C 6Z8

    Recruiting

  • Jewish General Hospital

    Montreal, Quebec, H3T 1E2

    Recruiting

  • l'Hôpital du Sacré-Cœur-de-Montréal

    Montreal, Quebec, H4J 1C5

    Recruiting

Other trials in Canada

Denmark3 sites, 3 recruiting

  • Aalborg Universitetshospital, Syd

    Aalborg, North Denmark, 9000

    Recruiting

  • Aarhus Universitetshospital, Skejby

    Aarhus, Central Jutland, 8200

    Recruiting

  • Rigshospitalet

    Copenhagen Ø, DK 2100

    Recruiting

Other trials in Denmark

Finland3 sites

  • Helsinki University Hospital - Comprehensive Cancer Center (HYKS - Syöpäkeskus)

    Helsinki, Uusimaa, 00029

    Active, not recruiting

  • Oulun yliopistollinen sairaala

    Oulu, 90220

    Active, not recruiting

  • Turku University Hospital

    Turku, Southwest Finland, 20520

    Active, not recruiting

Other trials in Finland

Netherlands3 sites

  • Albert Schweitzer Ziekenhuis, locatie Dordwijk

    Dordrecht, South Holland, 3318 AT

    Active, not recruiting

  • Maastricht UMC+

    Maastricht, Limburg, 6229 HX

    Active, not recruiting

  • Erasmus Medisch Centrum

    Rotterdam, South Holland, 3015 GD

    Active, not recruiting

Other trials in Netherlands

South Korea3 sites, 3 recruiting

  • Seoul National University Hospital

    Seoul, Seoul-teukbyeolsi [seoul], 03080

    Recruiting

  • Severance Hospital, Yonsei University Health System

    Seoul, Seoul-teukbyeolsi [seoul], 03722

    Recruiting

  • Samsung Medical Center

    Seoul, Seoul-teukbyeolsi [seoul], 06351

    Recruiting

Other trials in South Korea

Czechia2 sites, 2 recruiting

  • Fakultní nemocnice Brno Bohunice

    Brno, Brno-město, 625 00

    Recruiting

  • Fakultni nemocnice Kralovske Vinohrady

    Prague, Praha 10, 100 34

    Recruiting

Other trials in Czechia

Portugal2 sites

  • 2Ca Braga

    Braga, 4710-243

    Active, not recruiting

  • Instituto Português de Oncologia de Lisboa Francisco Gentil

    Lisbon, Lisbon District, 1099-023

    Active, not recruiting

Other trials in Portugal

Sweden2 sites

  • Falu Lasarett

    Falun, 791 31

    Active, not recruiting

  • Universitetssjukhuset Örebro

    Örebro, Örebro LÄN [se-18], 701 85

    Active, not recruiting

Other trials in Sweden

Taiwan2 sites, 2 recruiting

  • China Medical University Hospital

    Taichung, 404332

    Recruiting

  • Taichung Veterans General Hospital

    Taichung, 407

    Recruiting

Other trials in Taiwan

Slovenia1 site, 1 recruiting

  • University Medical Centre Ljubljana

    Ljubljana, 1000

    Recruiting

Other trials in Slovenia

About this study

Official title: A PHASE 3, OPEN-LABEL STUDY OF ELRANATAMAB MONOTHERAPY VERSUS ELOTUZUMAB, POMALIDOMIDE, DEXAMETHASONE (EPd) OR POMALIDOMIDE, BORTEZOMIB, DEXAMETHASONE (PVd) OR CARFILZOMIB, DEXAMETHASONE (Kd) IN PARTICIPANTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA WHO RECEIVED PRIOR ANTI-CD38 DIRECTED THERAPY

The purpose of this study is to learn about the study medicine called elranatamab.This study aims to compare elranatamab to other medicines for the treatment of MM (a type of cancer).

This study is seeking participants who:

Read more
  • Are 18 years of age or older and have MM.
  • Have received treatments before for MM.
  • Have MM that has returned or not responded to their most recent treatment.

Half of the participants will receive elranatamab. The other half of participants will receive a combination therapy selected by the study doctor. The selected combination therapy will include 2 to 3 different medicines commonly used to treat MM.

Elranatamab will be given as a shot under the skin at the study clinic about once a week. This may change to a smaller number of shots later in the study.

The medicines in the combination therapy will be taken by mouth (at home or at the study clinic) AND will be given either as:

  • a shot under the skin at the study clinic
  • through a needle in the vein at the study clinic The number of times these medicines will be taken depends on what combination therapy the study doctor selects.

Participants may continue to receive elranatamab or a combination therapy until their MM is no longer responding. The study team will see how each participant is doing with the study treatment during regular visits at the study clinic. The study team will continue to follow-up with participants after study treatment with telephone contacts (or visits).

The study will compare the experiences of people receiving elranatamab to those people receiving a combination therapy. This will help learn about the safety and how effective elranatamab is.

Being tested
Elranatamab, Elotuzumab, Pomalidomide, Dexamethasone, Bortezomib
Keywords
Elranatamab, B-Cell Maturation Antigen, BCMA, Bispecific antibody, BCMA-CD3 bispecific antibody, Myeloma, Multiple myeloma, Relapsed multiple myeloma, Refractory multiple myeloma, MagnetisMM, MagnetisMM-32, Pomalidomide, Elotuzumab, Bortezomib, Carfilzomib, PF-06863135
Medical subject headings
Multiple Myeloma, Neoplasms, Plasma Cell

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • ElranatamabDrug

    Elranatamab will be administered subcutaneously

  • ElotuzumabDrug

    Elotuzumab will be administered intravenously

  • PomalidomideDrug

    Pomalidomide will be administered orally

  • DexamethasoneDrug

    Dexamethasone will be administered orally

  • BortezomibDrug

    Bortezomib will be administered subcutaneously or intravenously

  • CarfilzomibDrug

    Carfilzomib will be administered intravenously

Study groups in NCT06152575
Study groupRoleWhat they receive
ElranatamabExperimentalParticipants will receive elranatamab monotherapy
Receives: Drug: Elranatamab
Investigator's ChoiceActive comparatorParticipants will receive either Elotuzumab, Pomalidomide and Dexamethasone (EPd), or Pomalidomide, Bortezomib and Dexamethasone (PVd), or Carfilzomib and Dexamethasone (Kd)
Receives: Drug: Elotuzumab; Drug: Pomalidomide; Drug: Dexamethasone; Drug: Bortezomib; Drug: Carfilzomib

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Progression free survival per International Myeloma Working Group criteria

    From date of randomization to date of progressive disease, discontinuation from study, death, or censoring, whichever occurs first

    Measured: Up to approximately 5 years

Secondary outcomes (17)

  1. Overall survival

    From date of randomization to date of discontinuation from study, death, or censoring, whichever occurs first

    Measured: Up to approximately 5 years

  2. Progression free survival on next-line treatment per International Myeloma Working Group criteria

    From date of randomization to date of second objective disease progression, discontinuation from the study, death, or censoring, whichever occurs first

    Measured: Up to approximately 5 years

  3. Objective response rate per International Myeloma Working Group criteria

    From date of randomization to date of progressive disease, discontinuation from study, death, or start of new anticancer therapy

    Measured: Up to approximately 5 years

  4. Duration of response per International Myeloma Working Group criteria

    From date of confirmed objective response to date of progressive disease, discontinuation from study, death, or censoring, whichever occurs first

    Measured: Up to approximately 5 years

  5. Very good partial response or better response rate per International Myeloma Working Group criteria

    From date of randomization to date of progressive disease, discontinuation from study, death, or start of new anticancer therapy, whichever occurs first

    Measured: Up to approximately 5 years

  6. Complete response rate per International Myeloma Working Group criteria

    From date of randomization to date of progressive disease, discontinuation from study, death, or start of new anticancer therapy, whichever occurs first

    Measured: Up to approximately 5 years

  7. Duration of complete response per International Myeloma Working Group criteria

    From date of confirmed complete response to date of progressive disease, discontinuation from study, death, or censoring, whichever occurs first

    Measured: Up to approximately 5 years

  8. Time to response per International Myeloma Working Group criteria

    From date of randomization to date of confirmed objective response

    Measured: Up to approximately 5 years

  9. Minimal residual disease negativity rate per International Myeloma Working Group criteria

    From date of randomization to date of progressive disease, discontinuation from study, death, or start of new anticancer therapy, whichever occurs first

    Measured: Up to approximately 5 years

  10. Sustained minimal residual disease negativity rate per International Myeloma Working Group criteria

    From date of randomization to date of progressive disease, discontinuation from study, death, or start of new anticancer therapy, whichever occurs first

    Measured: Up to approximately 5 years

  11. Duration of minimal residual disease negativity rate per International Myeloma Working Group criteria

    From date of minimal residual disease negativity to date of relapse, death, or censoring, whichever occurs first

    Measured: Up to approximately 5 years

  12. Frequency of treatment-emergent adverse events

    Measured: From date of first dose of study intervention up to 90 days after last study intervention administration

  13. Frequency of abnormal laboratory results

    Measured: From date of first dose of study intervention up to 90 days after last study intervention administration

  14. Free elranatamab serum trough concentration [Ctrough]

    Measured: From date of first dose of elranatamab up to approximately 14 days after last dose of elranatamab

  15. Elranatamab immunogenicity by anti-drug antibodies against elranatamab

    Measured: From date of first dose of elranatamab up to approximately 14 days after last dose of elranatamab

  16. Health-related quality of life by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire - Core 30

    Change from baseline scores

    Measured: From date of informed consent up to approximately 35 days after last administration of study intervention

  17. Health-related quality of life by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire - Myeloma 20

    Change from baseline scores

    Measured: From date of informed consent up to approximately 35 days after last administration of study intervention

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted30 Nov 2023
  2. Study start8 Feb 2024
  3. Primary completion30 Aug 2026 (estimated)
  4. Study completion30 Dec 2027 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
None (open label)
Enrolment
492 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT06152575
Sponsor's protocol ID
C1071032
Other IDs
MAGNETISMM-32, 2023-507871-23-00, 2023
Status last verified
Aug 2026
First submitted
17 Nov 2023
Last updated
24 Aug 2026
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
Individual data sharing
Yes: Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical\_trials/trial\_data\_and\_results/data\_requests.
Expanded access
Available

Questions about this trial

What is this clinical trial studying?

A Phase 3 study testing Elranatamab, Elotuzumab and Pomalidomide in people with Multiple Myeloma, run by Pfizer at 270 sites in 27 countries.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 6 inclusion and 12 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: looking for participants now, as of the sponsor's last update on 24 Aug 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 270 sites in United States, Brazil, United Kingdom, France, Japan and 22 more countries. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Pfizer CT.gov Call Center (1-800-718-1021, ClinicalTrials.gov_Inquiries@pfizer.com), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Progression free survival per International Myeloma Working Group criteria (time frame: Up to approximately 5 years). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT06152575.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 24 Aug 2026.

AzTrials uses cookies for analytics and advertising. You can accept or reject them; the site works either way. Privacy Policy.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in
Clinical Trial NCT06152575 | AzTrials